2. Search Result
Search Result
Results for "

motor symptoms

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148867
    UCM-1306

    2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl

    		 Dopamine Receptor Neurological Disease
    UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .
    UCM-1306
  • HY-14561A
    Idazoxan hydrochloride

    RX 781094 hydrochloride

    		 Adrenergic Receptor Imidazoline Receptor Neurological Disease Endocrinology
    Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .
    Idazoxan hydrochloride
  • HY-118406A
    Ethybenztropine hydrochloride

    Ponalid hydrochloride; UK 738 hydrochloride

    		 mAChR Neurological Disease
    Ethybenztropine hydrochloride (Ponalid hydrochloride) is an anticholinergic drug with antiparkinsonian activity. Ethybenztropine hydrochloride may also have dopamine reuptake inhibitory effects. Ethybenztropine hydrochloride is used to improve motor symptoms in patients with Parkinson's disease. Ethybenztropine hydrochloride exerts its inhibitory effects by regulating the balance of neurotransmitters .
    Ethybenztropine hydrochloride
  • HY-P10019
    Pegsebrenatide

    NLY01

    		 GCGR Neurological Disease
    Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .
    Pegsebrenatide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: